Dokter Nefrektomi radikal robotik terbaik di dunia — TOP 20

Dr. Barak Rosenzweig memimpin Layanan Onkologi Urologi di Sheba Medical Center di Israel. Beliau adalah seorang ahli bedah yang terdaftar di antara Dokter Terbaik Israel oleh Forbes. Dr. Rosenzweig berspesialisasi dalam mengobati tumor prostat, ginjal, kandung kemih, dan testis. Beliau berfokus pada bedah kanker robotik dan invasif minimal untuk menjaga fungsi organ.

• Menyelesaikan fellowship Onkologi Urologi di Memorial Sloan Kettering Cancer Center.
• Melakukan prostatektomi radikal robotik dan nefrektomi parsial yang menjaga ginjal.
• Dosen Klinis Senior di Universitas Tel Aviv dengan lebih dari 200 publikasi ilmiah.
• Menggunakan biopsi fusi berbasis MRI untuk deteksi kanker prostat dengan presisi tinggi.

Dokter ini adalah ahli urologi dan uro-onkologi yang sangat terkemuka, dengan spesialisasi dalam perawatan bedah kompleks untuk kanker prostat, ginjal, dan kandung kemih. Dengan keahlian luas dalam bedah robotik dan laparoskopi, dokter ini berperan penting dalam memajukan teknik urologi invasif minimal, termasuk penerapan sistem robotik Da Vinci. Saat ini, dokter tersebut memimpin Departemen Urologi di Centro Médico Teknon dan menjabat sebagai Kepala Departemen Urologi dan Transplantasi Ginjal di Hospital Clínic de Barcelona.

Diakui sebagai salah satu dari 100 dokter terbaik di Spanyol oleh Forbes, dokter ini menggabungkan keunggulan akademik dari Universitas Barcelona dan Mayo Clinic dengan fokus pada perawatan onkologi presisi tinggi dan transplantasi ginjal.

Prof. Dr. Cahide Yilmaz berspesialisasi dalam neurologi anak dengan pelatihan akademik dan klinis yang luas.

• Neurolog anak bersertifikat dengan pengalaman lebih dari 20 tahun
• Memiliki gelar doktor dari Universitas Fatih dalam bidang kesehatan dan penyakit anak
• Spesialisasi neurologi anak di Universitas Yüzüncü Yıl
• Profesor di Fakultas Kedokteran Universitas Yıldırım Beyazıt

Dr. Pazit Beckerman adalah kepala Registri Dialisis Israel. Beliau bekerja di Sheba Medical Center, rumah sakit yang menempati peringkat ke-7 secara global. Beliau berspesialisasi dalam penyakit ginjal kronis dan manajemen dialisis yang kompleks. Dr. Beckerman menyelesaikan fellowship pascadoktoral di University of Pennsylvania.

• Pernah menjabat sebagai Penjabat Direktur Nefrologi di Sheba Medical Center.
• Menangani cedera ginjal akut dan penyakit ginjal terkait hipertensi.
• Pakar dalam penyakit glomerulus, kehilangan protein, dan gangguan elektrolit.
• Anggota dewan Masyarakat Nefrologi dan Hipertensi Israel.

Pakar bedah robotik terkemuka, Dr. Canales, memimpin Departemen Bedah Umum & Pencernaan di Hospital Ruber Internacional dan termasuk dalam 5 besar ahli bedah terbaik di Spanyol.

• Spesialisasi lebih dari 30 tahun dalam teknik invasif minimal
• Kepala Unit Bedah Laparoskopi & Robotik sejak 2015
• Penulis lebih dari 70 publikasi ilmiah tentang metode bedah
• Masuk dalam daftar 100 Dokter Terbaik di Spanyol versi Forbes (2024)
• Menggunakan sistem robotik Da Vinci untuk pengangkatan tumor secara presisi

Professor Kim Hyun-hoe is a urologic cancer surgeon. He specializes in prostate and kidney cancer and robotic surgery. He directs Myongji Hospital’s Robotic Surgery Center and the Prostate & Kidney Cancer Center. He performed Korea’s first single-incision laparoscopy. At SNUH, he led more than 2,300 da Vinci cases over five years. He now uses the da Vinci Xi system.

He holds an MD, MS, and PhD from Seoul National University. He is a former director of SNUH Robotic Surgery and the Urology/Prostate Cancer Center. He is a past president of the Korean Society of Endourology and Robotics. He is a council member of the Korean Urological Association. His awards include the WCE Best Laparoscopy/Robotic Paper and the KUA Best Paper. He has also received several national academic honors. He contributes to next‑generation da Vinci research with Seoul National University and Intuitive Surgical. This was the first such collaboration in Asia.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Dorit Zilberman adalah ahli urologi senior di Sheba Medical Center di Israel. Beliau adalah pelopor bedah urologi robotik dan invasif minimal. Dr. Zilberman menangani kanker ginjal, kandung kemih, dan prostat. Beliau membantu meluncurkan program bedah robotik da Vinci di Sheba. Forbes Israel mengakui beliau sebagai salah satu dokter terbaik di negara tersebut.

• Penulis lebih dari 160 publikasi ilmiah di bidang onkologi urologi dan endourologi.
• Menyelesaikan pelatihan fellowship di Duke University Medical Center di AS.
• Melakukan prostatektomi robotik, litotripsi laser, dan bedah konservasi ginjal.
• Anggota Asosiasi Urologi Amerika dan Eropa serta Endourological Society.

Dr. Nir Kleinmann memimpin Unit Endourologi dan Batu Ginjal di Sheba Medical Center. Beliau adalah pelopor dalam bedah laser hemat ginjal untuk tumor kompleks. Forbes dan ResultMed menobatkannya sebagai salah satu Dokter Terbaik Israel untuk tahun 2025 dan 2026. Dr. Kleinmann menggunakan sistem laser ganda yang unik untuk menjaga fungsi organ selama perawatan kanker.

• Menyelesaikan fellowship urologi di Thomas Jefferson University dan McMaster University.
• Pakar dalam perawatan invasif minimal untuk UTUC, batu ginjal, dan kanker prostat.
• Berperan sebagai peneliti dalam uji coba OLYMPUS untuk kemoablasi non-bedah.
• Anggota American Endourology Society dengan lebih dari 60 publikasi ilmiah.

Kepala Urologi di Sheba Medical Center dan pelopor bedah urologi robotik di Israel – Dr. Dotan menggabungkan pengalaman puluhan tahun dengan teknik presisi canggih.

• Spesialis dalam kasus kanker ginjal dan prostat yang kompleks
• Melakukan prosedur robotik dan laparoskopi invasif minimal
• Penulis 50+ publikasi ilmiah di bidang uro-onkologi
• Terlatih di Memorial Sloan Kettering Cancer Center
• Pemimpin Masyarakat Uro-Onkologi Israel

Prof. Dr. Kadir Önem is a Professor of Urology at Medical Park Hospital in Samsun. He earned his MD and completed his urology residency at Istanbul University. He then completed a postdoctoral fellowship at Baylor College of Medicine in neuro-urology, reconstructive urology, and urologic oncology. He treats complex neuro-urological and reconstructive cases in adults and children. He has developed surgical techniques.

He is a principal investigator in several international Phase III–IV trials on neurogenic bladder and bladder cancer. He has more than 70 publications and book chapters. He serves as a reviewer for multiple journals.

Leadership and affiliations: President, Turkish Urological Association – Western Black Sea Branch (2025). ISCoS Prevention Committee (2025). EAU Neurourology Group (2023–2025). ICS Neurourology Committee (2023–2025). INUS Board (2023). Awards: TUA (2016, 2017, 2020, 2022) and ICS (2020).

Dr. Artur A. Antoniewicz, MD, PhD, adalah seorang ahli urologi dengan pengalaman lebih dari 20 tahun. Beliau telah memimpin Departemen Urologi di Rumah Sakit Spesialis Międzyleski di Warsawa selama 7 tahun. Beliau telah berafiliasi dengan rumah sakit tersebut selama lebih dari 20 tahun. Sejak 2018, beliau telah melakukan prosedur dengan bantuan robot di Pusat Perawatan Kanker Prostat.

Beliau lulus dari Fakultas Kedokteran Pertama di Universitas Kedokteran Warsawa. Beliau adalah spesialis urologi dan bedah umum (1992). Beliau pernah bekerja di Rumah Sakit Klinis Negara No. 1 di Warsawa, Departemen Urologi di Universitas Kedokteran Warsawa, dan Rumah Sakit Kereta Api di Warsawa. Beliau menyelesaikan fellowship dan pelatihan di Jerman, Prancis, Slovenia, dan Italia.

Beliau memperoleh sertifikasi FEBU pada tahun 1999. Beliau telah menjabat di Komite Ilmiah Asosiasi Urologi Polandia sejak tahun 2000. Beliau adalah anggota aktif Asosiasi Urologi Polandia, Dewan Urologi Eropa, Asosiasi Urologi Eropa, dan Société Internationale d’Urologie.

Dr. Eyup Koc adalah seorang internis dan nefrolog. Beliau menempuh pendidikan di Fakultas Kedokteran Universitas Istanbul – Cerrahpaşa dari tahun 1980 hingga 1986. Beliau menyelesaikan residensi Penyakit Dalam di Rumah Sakit Pelatihan dan Penelitian Atatürk Izmir dari tahun 1989 hingga 1994. Kemudian, beliau mengambil spesialisasi Nefrologi di Fakultas Kedokteran Universitas Gazi dari tahun 2005 hingga 2008.

Minat klinisnya meliputi hipertensi, gagal ginjal akut, gagal ginjal kronis, hemodialisis, dialisis peritoneal, transplantasi ginjal, glomerulonefritis, dan penyakit ginjal diabetik.

Prof. Dr. Gül Alço adalah ahli onkologi radiasi dengan pengalaman sekitar 27 tahun. Beliau menangani kanker payudara, paru-paru, prostat, saluran pencernaan, ginekologi, sistem saraf pusat, kepala dan leher, jaringan lunak, serta tulang dengan radioterapi.

Keahliannya meliputi radioterapi adaptif dan bedah radiasi (radiosurgery). Beliau menggunakan teknik radiasi canggih untuk memberikan perawatan yang dipersonalisasi dan berbasis bukti dalam lingkungan multidisiplin yang berpusat pada pasien.

Prof. Dr. Abdullah Sakin adalah profesor onkologi medis. Beliau menangani tumor padat, termasuk kanker paru-paru, payudara, gastrointestinal, genitourinari, ginekologi, kanker kepala dan leher, serta melanoma.

Beliau memberikan perawatan yang dipersonalisasi dan berbasis bukti. Perawatannya meliputi kemoterapi, terapi target, imunoterapi, terapi hormon, dan onkologi presisi. Beliau telah menulis lebih dari 200 publikasi ilmiah dan berpartisipasi dalam penelitian klinis internasional. Pekerjaan ini memajukan perawatan kanker yang berpusat pada pasien.

Dr. Paweł Grochowicz, MD, PhD, adalah seorang proktologis dengan pengalaman hampir 40 tahun. Beliau bekerja di Pusat Proktologi Warsawa di Rumah Sakit St. Elizabeth. Beliau menangani wasir, fistula dan abses anus, fisura anus, inkontinensia tinja, dan kista pilonidal. Beliau juga melakukan kolonoskopi dan polipektomi kolorektal.

Dari tahun 1979 hingga 2016, beliau bekerja di Unit Proktologi, Rumah Sakit Solec, sebuah pusat rujukan dan satu-satunya di Polandia. Sejak 2016, beliau bekerja di Pusat Proktologi Warsawa di Rumah Sakit St. Elizabeth. Di sana, beliau mengembangkan dan menerapkan metode baru serta menjalankan pekerjaan diagnostik, rehabilitasi, penelitian, dan pengajaran. Pusat ini merupakan kantor pusat Klub Koloproktologi Polandia.

Peran akademik dan penelitian: Institut Kedokteran Eksperimental dan Klinis, Akademi Ilmu Pengetahuan Polandia (1979–1997). Penerima beasiswa DAAD di LMU Munich (1983–1984). Rumah Sakit John Hunter, Universitas Newcastle, Australia (1989–1996). Di sana, beliau menjabat sebagai Direktur Unit Penelitian Transplantasi dan Pejabat Ilmiah Utama (1991–1996).

Dr. Przemyslaw Ciesielski adalah seorang ahli bedah umum. Ia menyelesaikan spesialisasi pada tahun 2008. Ia lulus dari Universitas Kedokteran Warsawa pada tahun 1999. Ia meraih gelar Doktor Ilmu Kedokteran pada tahun 2010. Disertasinya mengevaluasi pemeriksaan klinis dan rektoskopi untuk mendiagnosis penyakit kolorektal pada pasien dengan peningkatan risiko kanker kolorektal.

Pelatihan proktologi dan kolorektalnya mencakup kursus formal dan fellowship. Ia menyelesaikan Kursus Proktologi di Rumah Sakit St. Rota di Vercelli pada tahun 2021 dan 2022, serta di Cologne pada tahun 2016. Ia menjalani fellowship klinis dalam Bedah Umum di Universitas Kedokteran Wina pada tahun 2014 dan di Universitas Magdeburg pada tahun 2015. Ia menjalani beberapa fellowship di Departemen Proktologi, Rumah Sakit Solec di Warsawa dari tahun 2005 hingga 2013. Ia menghadiri lokakarya bedah kolorektal tingkat lanjut di Poznan dan Lodz. Ia juga menyelesaikan kursus di Rumah Sakit St. Mark di London, termasuk "Frontiers in Colorectal Diseases" dan "Advanced Colorectal Workshop".

Prof. Jakub Dobruch, MD, PhD, adalah seorang ahli urologi dan ahli bedah robotik. Beliau adalah Profesor Urologi dan Kepala Departemen Urologi di CMKP (sejak 2015). Beliau menjabat sebagai Wakil Presiden Asosiasi Urologi Polandia (2022–2026). Beliau menjadi Profesor Ilmu Kedokteran pada tahun 2021 dan Profesor CMKP pada tahun 2019. Beliau memperoleh habilitasi pada tahun 2014 dan gelar spesialis urologi pada tahun 2008.

Fokus klinis: bedah minimal invasif dan robotik untuk kanker prostat, kandung kemih, dan ginjal. Beliau telah bekerja sebagai ahli bedah laparoskopi independen sejak tahun 2005. Beliau melakukan rekonstruksi endoskopi gabungan. Beliau berlatih di pusat-pusat terkemuka di New York, Berlin, Leipzig, Salzburg, Miami, Dallas, dan Winston-Salem.

Penelitian berfokus pada onkologi urologi, terutama kanker kandung kemih dan prostat. Beliau telah memimpin proyek-proyek yang didanai oleh CMKP dan KBN. Beliau adalah anggota EAU Young Academic Urologists dan mengawasi proyek-proyek kanker kandung kemih. Habilitasinya berfokus pada margin bedah setelah prostatektomi radikal.